| 翻訳と辞書 |
| Reagan-Udall Foundation ： ウィキペディア英語版 |
Reagan-Udall Foundation
The Reagan-Udall Foundation is a private nonprofit (501c3) organization, created to support the mission of the U.S. Food and Drug Administration (FDA) to help equip FDA staff with the highest caliber, regulatory science and technology in order to enhance the safety and effectiveness of FDA regulated products. Although it was mandated by Congress in the Food and Drug Administration Amendments Act of 2007 to help support and promote FDA's regulatory science priorities, it is independent of the agency, with its own Board of Directors, staff and research agenda. The Reagan-Udall Foundation creates public-private partnerships to advance research in regulatory science, enhance medical decision making, and promote innovation. It also advances regulatory science through fellowships and other training programs, both for private scientists and for FDA staff.
== Current activities and projects ==
The Reagan-Udall Foundation is collaborating with FDA in several high-priority scientific areas identified as part of the agency's innovation strategy. These include food safety, novel approaches in the development of therapies to fight tuberculosis, and methodologies for post-market product surveillance. Two specific examples:
1) Funded by the Bill & Melinda Gates Foundation, the Reagan-Udall Foundation is an active participant in the Critical Path to TB Drug Regiments (CPTR), a global initiative co-founded by the Bill & Melinda Gates Foundation, the Critical Path Institute, and the TB Alliance in March 2010 to accelerate the development of new tuberculosis (TB) treatment regimens. The Foundation's role is to convene and facilitate collaboration and dialogue between the CPTR team and a broad range of international TB stakeholders including regulatory and academic scientists, drug developers, advocates, and other NGOs, to identify, prioritize and work toward resolving regulatory science issues and challenges.
2) Funded by the Susan G. Komen for the Cure, the Reagan-Udall Foundation is convening a Systems Toxicology Project with the ultimate goal of directly identifying common biological intermediates for toxicity in two classes of oncology drugs, then correlating them to an adverse event. This could enable future research within the drug class to mitigate toxic effects through dosing modification, alternative treatments, or potentially develop a new regulatory tool that would assist in future drug safety evaluation. By having an independent, third party convener, like the Reagan-Udall Foundation, multiple companies can be readily involved, along with toxicologists, oncologists and other scientists from the FDA, National Institutes of Health and academia.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Reagan-Udall Foundation」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|